US20180193637A1 - Process and system for iontophoretic wrinkle reduction - Google Patents
Process and system for iontophoretic wrinkle reduction Download PDFInfo
- Publication number
- US20180193637A1 US20180193637A1 US15/918,441 US201815918441A US2018193637A1 US 20180193637 A1 US20180193637 A1 US 20180193637A1 US 201815918441 A US201815918441 A US 201815918441A US 2018193637 A1 US2018193637 A1 US 2018193637A1
- Authority
- US
- United States
- Prior art keywords
- patch
- skin
- assembly
- chemical composition
- current
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title abstract description 25
- 230000037331 wrinkle reduction Effects 0.000 title abstract description 6
- 239000000017 hydrogel Substances 0.000 claims description 8
- 238000004891 communication Methods 0.000 claims description 4
- 239000010410 layer Substances 0.000 claims 3
- 239000012790 adhesive layer Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 23
- 239000000126 substance Substances 0.000 abstract description 22
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 239000000853 adhesive Substances 0.000 abstract description 5
- 230000001070 adhesive effect Effects 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 28
- 230000000712 assembly Effects 0.000 description 15
- 238000000429 assembly Methods 0.000 description 15
- 239000000758 substrate Substances 0.000 description 9
- 230000037303 wrinkles Effects 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- -1 hydroxyl ions Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D44/00—Other cosmetic or toiletry articles, e.g. for hairdressers' rooms
- A45D44/22—Face shaping devices, e.g. chin straps; Wrinkle removers, e.g. stretching the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/22—Electromedical belts, e.g. neck chains, armbands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/328—Applying electric currents by contact electrodes alternating or intermittent currents for improving the appearance of the skin, e.g. facial toning or wrinkle treatment
Definitions
- the present disclosure relates and is directed to a process or method of use and a system including a disposable patch to treat wrinkles and fine lines with a chemical composition administered by iontophoresis.
- moisturizers containing amino acids play a significant role in skin care by increasing skin elasticity and smoothing the skin.
- anti-aging active agents are known to change the skin condition by smoothing and tightening.
- Chemical compositions may be administered topically, such as lotions, or administered through transdermal patches. Additionally, chemical compositions may be administered by direct injection. Chemical compositions presently available include those which moisturize the outer skin or epidermis. Other compositions tend to promote cell growth in the skin. Other treatments of wrinkles and fine lines include botulinum toxin (marketed under the trademark Botox®) which inhibits neurotransmission in nerve cells, thereby causing contracted muscles to relax.
- Botox® botulinum toxin
- Fahim U.S. Pat. No. 4,372,296 discloses topical treatment of acne with zinc salt and ascorbic acid in a pharmaceutical carrier which is applied with ultra sonic vibrations.
- Stephen et al. (U.S. Pat. No. 4,979,938) disclose a method of treating acne using an applicator electrode having a solution capable of producing hydroxyl ions.
- An applicator electrode is placed against the skin and a voltage differential is applied to produce and drive hydroxyl ions into the skin tissue.
- Sun et al. U.S. Pat. No. 7,479,133 discloses a device for treating acne or rosacea by applying an electrical charge with two conductive electrodes in communication with a carrier containing an electrolyte.
- Durand patent publications U.S. Patent Application Publication Nos. 2009/0048556 and 2009/0149800 disclose a drug delivery system including a pair of electrodes coupled to drug reservoirs 24 controlled by a microprocessor 12 .
- the microprocessor may be programmed through a wireless signal receiver.
- the present disclosure is directed to a process or method of use and a system for wrinkle reduction.
- the system includes a patch assembly applied and adhesively secured to the skin of the consumer.
- Each patch assembly includes a substantially planar top sheet and a substantially planar substrate. Connectors or snaps pass through the top sheet and substrate. On the substrate is a layer of a chemical composition including active ingredients and an adhesive in order to adhere to the skin.
- the patch assembly or assemblies are connectable to a detachable electronic locket assembly.
- the locket assembly may include a housing to form an enclosure. Within the enclosure of the housing is a battery which powers a microprocessor based controller or printed circuit board (PCB).
- the controller is wired to a pair of electrodes through wires to a wiring harness.
- the housing, the battery and the controller are suspended from the wiring harness.
- the patch assembly or assemblies are positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin.
- a pair of electrodes arc connected to the connectors or snaps of the patch assembly.
- a current is applied from the locket assembly through the electrodes into the chemical composition of the patch assembly for a selected time period.
- the active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin.
- the current is stopped and the patch assembly is removed.
- the patch assembly may then be disconnected from the locket assembly.
- the patch assembly may thereafter be discarded and the locket assembly may be reused.
- FIG. 1 is an illustration of a first preferred embodiment of a process and system for iontophoretic wrinkle reduction in accordance with the present disclosure
- FIG. 2A illustrates a prospective view and FIG. 2B is an exploded view of patch assemblies of the first preferred embodiment of the present disclosure
- FIG. 3A is a patch assembly of a second preferred embodiment while FIG. 3B is an exploded view of the patch assembly shown in FIG. 3A ;
- FIG. 4 illustrates an exploded view of an electronic locket assembly utilized in connection with the present disclosure
- FIGS. 5A, 5B and 5C show alternate views of the lock assembly shown in FIG. 4 ;
- FIG. 5D is a sectional view taken through section line D-D of FIG. 5A ;
- FIG. 6 is a diagrammatic flow chart of the process or method of application of the present disclosure.
- FIG. 7 illustrates a schematic representation of delivery of the electric current cycle during usage of the present disclosure.
- the present disclosure includes at least two preferred embodiments—a first preferred embodiment utilized on the skin surrounding the eyes of a consumer and a second preferred embodiment utilized on the forehead and bridge of the nose of a consumer.
- FIG. 1 is an illustration of the first preferred embodiment 10 of the present disclosure surrounding the eyes of a consumer.
- a pair of patch assemblies 12 and 14 are applied and adhesively secured to the skin of a consumer surrounding the eyes.
- FIG. 2A illustrates a perspective view of the patch assemblies 12 and 14 prior to use and FIG. 2B is an exploded view of the patch assemblies 12 and 14 illustrating the components thereof.
- Each of the patch assemblies 12 and 14 may include a substantially planar top sheet 16 and 18 , respectively.
- the patch assemblies 12 and 14 may also include a substantially planar substrate 20 and 22 , respectively.
- top sheet 16 and 18 and the substrates 20 and 22 each have holes or apertures which are aligned in order to receive conductive connectors or snaps 24 and 26 that pass therethrough.
- Each of the connectors or snaps may be in two-part form. In one non-limiting example, known type electro-mechanical connectors may be utilized.
- Adjacent and on the substrates 20 and 22 are layers of a chemical composition, which may be in the nature of a hydrogel 28 and 30 , respectively.
- the hydrogel 28 and 30 will contain active ingredients of the chemical composition and may also include an adhesive in order to adhere to the skin.
- the active ingredients may include hyaluronic acid, stressed yeast cell lysate, yeast cell derivative, and cross-linked synthetically derived protein.
- the hyaluronic acid may be in the range of 0.1 to 15%.
- the hydrogel 28 and 30 are in fluid communication with the connections or snaps 24 and 26 . Accordingly, current or voltage delivered to the connectors or snaps is delivered to the hydrogel.
- a conductor 21 shown in FIGS. 3A-F and 4 A- 4 E, such as a conductive carbon ink, may be added to the substrate layers 20 , 22 to improve the conductivity of the electrode assembly.
- the patch assemblies 12 and 14 may be stored and transported on a release liner sheet 32 .
- the patch assemblies may be easily peeled off or removed from the liner sheet.
- the entire assemblies and the liner sheet 32 may be stored in a pouch 34 .
- FIG. 3A A second preferred embodiment of the present disclosure to be applied to the forehead and bridge of the nose is shown in assembled form in FIG. 3A and is shown exploded in FIG. 3B .
- the second preferred embodiment includes a patch assembly 42 shown fully assembled in FIG. 3A prior to use.
- the patch assembly 42 may include a substantially planar top sheet 44 and an aligned substantially planar substrate 46 .
- the top sheet 44 and substrate 46 each include aligned holes or apertures to receive a pair of connectors or snaps 48 and 50 .
- the patch assembly includes a layer of chemical composition in the hydrogel 52 .
- the entire patch assembly 42 may be transported and stored on a liner sheet 54 .
- the patch assembly 42 and the liner sheet may be stored in a pouch 56 .
- the patch assemblies are disposable after use.
- the patch assemblies are connectable to an electronic locket assembly 60 .
- FIG. 4 illustrates an exploded view of the electronic locket assembly 60 .
- FIGS. 5A, 5B and 5C show alternate views of the locket assembly 60 with FIG. 5D illustrating a sectional view taken through section line D-D of FIG. 5A .
- the locket assembly 60 may include a front housing 62 which mates with a rear housing 64 to form an enclosure. Attached to the housing may be an optional clasp or clip 66 .
- a battery 68 Within the enclosure of the housing is a battery 68 which powers a microprocessor based controller or printed circuit board (PCB) 70 .
- a contact or contacts 72 connect the battery 68 to the controller 70 .
- PCB printed circuit board
- the microprocessor based controller 70 is, in turn, wired to a pair of electrodes 74 and 76 through wires or a wiring harness 78 .
- the housing 62 and 64 , the battery 68 and controller 70 may hang from or be suspended from the wiring harness 78 .
- the process and system of the present disclosure uses iontophoresis as the motive force for transdermal delivery of a defined amount of active ingredients.
- the patch assembly or assemblies are removed from the storage pouch and removed from the liner sheet and then positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin.
- the adhesive in the chemical composition serves to removably secure the patch assembly to the skin.
- the pair of electrodes 74 and 76 are connected to the connectors or snaps of the patch assembly either in advance of application to the skin or after application. The process is continued by electronically activating the patch assembly.
- a current is applied from the locket assembly 60 through the electrodes 74 and 76 into the chemical composition of the patch assembly for a selected time period.
- the active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin or achieve other beneficial results.
- the current optionally may be reversed once or at least twice, for example, as illustrated in FIG. 7 .
- the current is stopped and the patch assembly is removed from the skin.
- the patch assembly may be disconnected from the locket assembly 60 .
- the patch assembly may thereafter be discarded.
- any residue of the chemical composition may be massaged into the skin.
- the procedure may be periodically repeated.
- FIG. 6 illustrates a diagrammatic, flow chart of the process or method of application of the current during the delivery cycle of the disclosure.
- the microprocessor based controller 70 will conduct a self initialization test as shown in Box 84 .
- the process can be started conventionally by a button or switch or may be activated by a change in resistance between the electrodes triggered by skin contact.
- a solid red LED or other indicator will be provided as shown at Box 86 and the device will not be used. If the initialization test is satisfactory, as shown in Diamond 88 , proper functioning will be indicated by a green LED as shown at Box 90 .
- FIG. 7 illustrates a schematic representation of the current cycle.
- the current will be ramped up and then held for a predetermined time period.
- the power supply and/or the controller can be configured to apply no current through the electrodes 74 and 76 . Thereafter, the current will be ramped down and the polarity changed.
- a mid-cycle self diagnostic test may be performed by the controller as shown at box 98 . If an error is detected, a red LED will be displayed as shown at Box 100 and the procedure will be terminated. If the diagnostic test is satisfactory, as shown at Diamond 102 , the procedure will be continued until the time period is completed as shown at Diamond 104 . When the time period has been completed, the green light ceases to blink and remains on for a period of time to indicate the end of the procedure as shown at Box 106 .
- the patch assembly is removed from the skin and the locket assembly 60 is detached from the patch assembly.
- the locket assembly may be reused.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
- Massaging Devices (AREA)
Abstract
A method and related systems and apparatuses for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin or the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.
Description
- Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by reference under 37 CFR 1.57.
- This application is a continuation of copending U.S. patent application Ser. No. 14/298,190, filed on Jun. 6, 2014, which is a continuation of U.S. patent application Ser. No. 12/970,224, filed Dec. 16, 2010, now U.S. Pat. No. 8,747,383, which claims priority to U.S. Provisional Patent Application Ser. No. 61/288,088, filed Dec. 18, 2009, each are incorporated in their entireties herein by reference and for all purposes.
- The present disclosure relates and is directed to a process or method of use and a system including a disposable patch to treat wrinkles and fine lines with a chemical composition administered by iontophoresis.
- There are various known procedures and various known chemical compositions for treating, reducing or preventing fine lines or wrinkles of the facial skin. It is known that moisturizers containing amino acids play a significant role in skin care by increasing skin elasticity and smoothing the skin. In addition, anti-aging active agents are known to change the skin condition by smoothing and tightening.
- Chemical compositions may be administered topically, such as lotions, or administered through transdermal patches. Additionally, chemical compositions may be administered by direct injection. Chemical compositions presently available include those which moisturize the outer skin or epidermis. Other compositions tend to promote cell growth in the skin. Other treatments of wrinkles and fine lines include botulinum toxin (marketed under the trademark Botox®) which inhibits neurotransmission in nerve cells, thereby causing contracted muscles to relax.
- In order to increase the speed and effectiveness of delivery of chemical compositions for treatment, it is known to utilize sonic vibrations. For example, Fahim (U.S. Pat. No. 4,372,296) discloses topical treatment of acne with zinc salt and ascorbic acid in a pharmaceutical carrier which is applied with ultra sonic vibrations.
- Stephen et al. (U.S. Pat. No. 4,979,938) disclose a method of treating acne using an applicator electrode having a solution capable of producing hydroxyl ions. An applicator electrode is placed against the skin and a voltage differential is applied to produce and drive hydroxyl ions into the skin tissue.
- Sun et al. (U.S. Pat. No. 7,479,133) discloses a device for treating acne or rosacea by applying an electrical charge with two conductive electrodes in communication with a carrier containing an electrolyte.
- More recently, the Durand patent publications (U.S. Patent Application Publication Nos. 2009/0048556 and 2009/0149800) disclose a drug delivery system including a pair of electrodes coupled to
drug reservoirs 24 controlled by amicroprocessor 12. The microprocessor may be programmed through a wireless signal receiver. - Notwithstanding the forgoing, there remains a need for an effective, simple, non-invasive and non-surgical process and system utilizing a disposable patch for treating wrinkles and fine lines.
- There also remains a need for a process and system utilizing a disposable patch for wrinkle reduction which may be manufactured at low-cost and high volume.
- There also remains a need for a process and system utilizing a disposable patch for wrinkle reduction with precision timing of delivery of active ingredients.
- There also remains a need for an apparatus having an adhesive disposable patch with a plurality of active ingredients, a power supply, and a controller in communication with the power supply controlling current using a ramping current profile.
- The present disclosure is directed to a process or method of use and a system for wrinkle reduction.
- The system includes a patch assembly applied and adhesively secured to the skin of the consumer. Each patch assembly includes a substantially planar top sheet and a substantially planar substrate. Connectors or snaps pass through the top sheet and substrate. On the substrate is a layer of a chemical composition including active ingredients and an adhesive in order to adhere to the skin.
- The patch assembly or assemblies are connectable to a detachable electronic locket assembly. The locket assembly may include a housing to form an enclosure. Within the enclosure of the housing is a battery which powers a microprocessor based controller or printed circuit board (PCB). The controller is wired to a pair of electrodes through wires to a wiring harness. The housing, the battery and the controller are suspended from the wiring harness.
- In order to use the disclosed embodiments, the patch assembly or assemblies are positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin. A pair of electrodes arc connected to the connectors or snaps of the patch assembly.
- A current is applied from the locket assembly through the electrodes into the chemical composition of the patch assembly for a selected time period. The active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin. After a selected period of time, the current is stopped and the patch assembly is removed.
- The patch assembly may then be disconnected from the locket assembly. The patch assembly may thereafter be discarded and the locket assembly may be reused.
-
FIG. 1 is an illustration of a first preferred embodiment of a process and system for iontophoretic wrinkle reduction in accordance with the present disclosure; -
FIG. 2A illustrates a prospective view andFIG. 2B is an exploded view of patch assemblies of the first preferred embodiment of the present disclosure; -
FIG. 3A is a patch assembly of a second preferred embodiment whileFIG. 3B is an exploded view of the patch assembly shown inFIG. 3A ; -
FIG. 4 illustrates an exploded view of an electronic locket assembly utilized in connection with the present disclosure; -
FIGS. 5A, 5B and 5C show alternate views of the lock assembly shown inFIG. 4 ; -
FIG. 5D is a sectional view taken through section line D-D ofFIG. 5A ; -
FIG. 6 is a diagrammatic flow chart of the process or method of application of the present disclosure; and -
FIG. 7 illustrates a schematic representation of delivery of the electric current cycle during usage of the present disclosure. - The embodiments discussed herein are merely illustrative of specific manners in which to make and use the disclosed embodiments and are not to be interpreted as limiting the scope of the present disclosure.
- While the disclosure has been described with a certain degree of particularity, it is to be noted that many modifications may be made in the details of the construction and the arrangement of selected components without departing from the spirit and scope of this disclosure. It is understood that the disclosure is not limited to the embodiments set forth herein for purposes or exemplification.
- The present disclosure includes at least two preferred embodiments—a first preferred embodiment utilized on the skin surrounding the eyes of a consumer and a second preferred embodiment utilized on the forehead and bridge of the nose of a consumer.
- Referring to the drawings in detail,
FIG. 1 is an illustration of the firstpreferred embodiment 10 of the present disclosure surrounding the eyes of a consumer. As will be described herein in detail, a pair of 12 and 14 are applied and adhesively secured to the skin of a consumer surrounding the eyes.patch assemblies -
FIG. 2A illustrates a perspective view of the 12 and 14 prior to use andpatch assemblies FIG. 2B is an exploded view of the 12 and 14 illustrating the components thereof.patch assemblies - Each of the
12 and 14 may include a substantially planarpatch assemblies 16 and 18, respectively. Thetop sheet 12 and 14 may also include a substantiallypatch assemblies 20 and 22, respectively.planar substrate - The
16 and 18 and thetop sheet 20 and 22 each have holes or apertures which are aligned in order to receive conductive connectors or snaps 24 and 26 that pass therethrough. Each of the connectors or snaps may be in two-part form. In one non-limiting example, known type electro-mechanical connectors may be utilized.substrates - Adjacent and on the
20 and 22 are layers of a chemical composition, which may be in the nature of asubstrates 28 and 30, respectively. Thehydrogel 28 and 30 will contain active ingredients of the chemical composition and may also include an adhesive in order to adhere to the skin. The active ingredients may include hyaluronic acid, stressed yeast cell lysate, yeast cell derivative, and cross-linked synthetically derived protein. The hyaluronic acid may be in the range of 0.1 to 15%.hydrogel - The
28 and 30 are in fluid communication with the connections or snaps 24 and 26. Accordingly, current or voltage delivered to the connectors or snaps is delivered to the hydrogel. Alternatively or additionally, a conductor 21 (shown inhydrogel FIGS. 3A-F and 4A-4E), such as a conductive carbon ink, may be added to the substrate layers 20, 22 to improve the conductivity of the electrode assembly. - The
12 and 14 may be stored and transported on apatch assemblies release liner sheet 32. The patch assemblies may be easily peeled off or removed from the liner sheet. The entire assemblies and theliner sheet 32 may be stored in apouch 34. - A second preferred embodiment of the present disclosure to be applied to the forehead and bridge of the nose is shown in assembled form in
FIG. 3A and is shown exploded inFIG. 3B . - The second preferred embodiment includes a
patch assembly 42 shown fully assembled inFIG. 3A prior to use. Thepatch assembly 42 may include a substantially planartop sheet 44 and an aligned substantiallyplanar substrate 46. Thetop sheet 44 andsubstrate 46 each include aligned holes or apertures to receive a pair of connectors or snaps 48 and 50. - The patch assembly includes a layer of chemical composition in the
hydrogel 52. Theentire patch assembly 42 may be transported and stored on aliner sheet 54. Thepatch assembly 42 and the liner sheet may be stored in apouch 56. - In a preferred arrangement, the patch assemblies are disposable after use. In each embodiment, the patch assemblies are connectable to an
electronic locket assembly 60. -
FIG. 4 illustrates an exploded view of theelectronic locket assembly 60.FIGS. 5A, 5B and 5C show alternate views of thelocket assembly 60 withFIG. 5D illustrating a sectional view taken through section line D-D ofFIG. 5A . Thelocket assembly 60 may include afront housing 62 which mates with arear housing 64 to form an enclosure. Attached to the housing may be an optional clasp orclip 66. Within the enclosure of the housing is abattery 68 which powers a microprocessor based controller or printed circuit board (PCB) 70. A contact orcontacts 72 connect thebattery 68 to thecontroller 70. - The microprocessor based
controller 70 is, in turn, wired to a pair of 74 and 76 through wires or aelectrodes wiring harness 78. - The
62 and 64, thehousing battery 68 andcontroller 70 may hang from or be suspended from thewiring harness 78. - The process and system of the present disclosure uses iontophoresis as the motive force for transdermal delivery of a defined amount of active ingredients.
- In order to use the system of the present disclosure, initially, the patch assembly or assemblies are removed from the storage pouch and removed from the liner sheet and then positioned and aligned on the skin so that the chemical composition is in contact with and applied to the skin. The adhesive in the chemical composition serves to removably secure the patch assembly to the skin.
- The pair of
74 and 76 are connected to the connectors or snaps of the patch assembly either in advance of application to the skin or after application. The process is continued by electronically activating the patch assembly.electrodes - Thereafter, a current is applied from the
locket assembly 60 through the 74 and 76 into the chemical composition of the patch assembly for a selected time period. The active ingredients of the chemical composition are propelled into the skin of the consumer in order to relax the skin or achieve other beneficial results. After a selected period of time, the current optionally may be reversed once or at least twice, for example, as illustrated inelectrodes FIG. 7 . Eventually, the current is stopped and the patch assembly is removed from the skin. The patch assembly may be disconnected from thelocket assembly 60. The patch assembly may thereafter be discarded. - As an additional step or measure, after the patch assembly is removed, any residue of the chemical composition may be massaged into the skin. The procedure may be periodically repeated.
-
FIG. 6 illustrates a diagrammatic, flow chart of the process or method of application of the current during the delivery cycle of the disclosure. After start of the procedure, as shown inBox 82, the microprocessor basedcontroller 70 will conduct a self initialization test as shown inBox 84. The process can be started conventionally by a button or switch or may be activated by a change in resistance between the electrodes triggered by skin contact. - If the initialization test does not result in an affirmative outcome, a solid red LED or other indicator will be provided as shown at
Box 86 and the device will not be used. If the initialization test is satisfactory, as shown inDiamond 88, proper functioning will be indicated by a green LED as shown atBox 90. - Current to the device will be permitted to ramp up and a timer will be started as shown at
Box 92. While the current is being delivered through the chemical composition and into the skin, a blinking green LED will be employed, as shown atBox 94. - The polarity of the current will be cycled or alternated as shown at
Box 96.FIG. 7 illustrates a schematic representation of the current cycle. The current will be ramped up and then held for a predetermined time period. During the predetermined time period, the power supply and/or the controller can be configured to apply no current through the 74 and 76. Thereafter, the current will be ramped down and the polarity changed.electrodes - Additionally, a mid-cycle self diagnostic test may be performed by the controller as shown at
box 98. If an error is detected, a red LED will be displayed as shown atBox 100 and the procedure will be terminated. If the diagnostic test is satisfactory, as shown atDiamond 102, the procedure will be continued until the time period is completed as shown atDiamond 104. When the time period has been completed, the green light ceases to blink and remains on for a period of time to indicate the end of the procedure as shown atBox 106. - Thereafter, the patch assembly is removed from the skin and the
locket assembly 60 is detached from the patch assembly. The locket assembly may be reused. - If, at any time after the cycle has started, one of the electrodes or patch assemblies falls off, an error condition is signaled. If not reconnected within a reasonable time, the system defaults to an off position.
- Whereas, the present disclosure has been described in relation to the drawings attached hereto, it should be understood that other and further modifications, apart from those shown or suggested herein, may be made within the spirit and scope of this disclosure.
Claims (1)
1. A wrinkle-reducing apparatus, comprising:
a patch comprising a hydrogel layer coupled with an adhesive layer; and
a power supply in communication with the hydrogel layer via an electrode,
wherein the power supply is configured to apply an iontophoretic current to the hydrogel layer through the electrode.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/918,441 US20180193637A1 (en) | 2009-12-18 | 2018-03-12 | Process and system for iontophoretic wrinkle reduction |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28808809P | 2009-12-18 | 2009-12-18 | |
| US12/970,224 US8747383B2 (en) | 2009-12-18 | 2010-12-16 | Process and system for iontophoretic wrinkle reduction |
| US14/298,190 US9913977B2 (en) | 2009-12-18 | 2014-06-06 | Process and system for iontophoretic wrinkle reduction |
| US15/918,441 US20180193637A1 (en) | 2009-12-18 | 2018-03-12 | Process and system for iontophoretic wrinkle reduction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/298,190 Continuation US9913977B2 (en) | 2009-12-18 | 2014-06-06 | Process and system for iontophoretic wrinkle reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20180193637A1 true US20180193637A1 (en) | 2018-07-12 |
Family
ID=44167938
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/970,224 Active 2032-03-26 US8747383B2 (en) | 2009-12-18 | 2010-12-16 | Process and system for iontophoretic wrinkle reduction |
| US14/298,190 Active US9913977B2 (en) | 2009-12-18 | 2014-06-06 | Process and system for iontophoretic wrinkle reduction |
| US15/918,441 Abandoned US20180193637A1 (en) | 2009-12-18 | 2018-03-12 | Process and system for iontophoretic wrinkle reduction |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/970,224 Active 2032-03-26 US8747383B2 (en) | 2009-12-18 | 2010-12-16 | Process and system for iontophoretic wrinkle reduction |
| US14/298,190 Active US9913977B2 (en) | 2009-12-18 | 2014-06-06 | Process and system for iontophoretic wrinkle reduction |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US8747383B2 (en) |
| EP (1) | EP2512283A4 (en) |
| RU (1) | RU2012130389A (en) |
| WO (1) | WO2011075646A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100286590A1 (en) * | 2009-05-08 | 2010-11-11 | Isis Biopolymer Llc | Iontophoretic device with improved counterelectrode |
| US20110092881A1 (en) * | 2009-05-08 | 2011-04-21 | Isis Biopolymer Inc. | Iontophoretic device with contact sensor |
| US8747383B2 (en) | 2009-12-18 | 2014-06-10 | University Medical Pharmaceuticals Corp. | Process and system for iontophoretic wrinkle reduction |
| US20130012891A1 (en) * | 2011-07-05 | 2013-01-10 | Yossi Gross | Skin-treatment and drug-delivery devices |
| CN109688864A (en) * | 2016-05-02 | 2019-04-26 | 普尔普勒技术公司 | System and method for showing digital picture on Digital Image Display box |
| EP3520649B1 (en) * | 2016-09-27 | 2021-01-20 | Panasonic Intellectual Property Management Co., Ltd. | Thin film affixing device |
| US11642504B2 (en) * | 2017-08-07 | 2023-05-09 | Nippon Telegraph And Telephone Corporation | Sheet mask comprising a battery part |
| US10092478B1 (en) * | 2017-09-06 | 2018-10-09 | Noah Amit | Method and system for treating skin associated with the face and neck |
| WO2024080248A1 (en) * | 2022-10-13 | 2024-04-18 | ヤーマン株式会社 | Beauty mask |
| CN118718238B (en) * | 2024-09-02 | 2024-11-22 | 北京意安平顺网络科技有限公司 | Iontophoresis patch for facial skin and method of manufacture |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050000455A1 (en) * | 2003-07-01 | 2005-01-06 | Havermans Cornelis Christianus Franciscus | Milking installation |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4372296A (en) | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
| US4406658A (en) * | 1981-03-06 | 1983-09-27 | Medtronic, Inc. | Iontophoretic device with reversible polarity |
| US4702732A (en) * | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
| JPS6499A (en) | 1987-03-17 | 1989-01-05 | Nippon Kayaku Co Ltd | 23-phenylsteroids and production thereof |
| US4979938A (en) | 1989-05-11 | 1990-12-25 | Iomed, Inc. | Method of iontophoretically treating acne, furuncles and like skin disorders |
| US5505949A (en) * | 1994-10-13 | 1996-04-09 | Benitez; Juan E. | Topical treatment for acne |
| JPH11505158A (en) | 1995-05-15 | 1999-05-18 | アルザ・コーポレーション | Electric transport device with reusable controller |
| JP2768456B2 (en) | 1995-12-22 | 1998-06-25 | 株式会社ジャパンギャルズ | Makeup mask |
| US6175763B1 (en) * | 1996-03-29 | 2001-01-16 | Alza Corporation | Electrotransport drug delivery device having tactile signaling means |
| FR2755372B1 (en) * | 1996-11-07 | 1998-12-24 | Elf Aquitaine | IONOPHORESIS DEVICE COMPRISING AT LEAST ONE MEMBRANE ELECTRODE ASSEMBLY FOR THE TRANSCUTANEOUS ADMINISTRATION OF ACTIVE PRINCIPLES TO A SUBJECT |
| US5882677A (en) * | 1997-09-30 | 1999-03-16 | Becton Dickinson And Company | Iontophoretic patch with hydrogel reservoir |
| EP1674044B1 (en) * | 1997-10-09 | 2015-08-19 | Aesculap AG | Systems for organ resection |
| US6792306B2 (en) * | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
| US6590441B2 (en) | 2001-06-01 | 2003-07-08 | Qualcomm Incorporated | System and method for tuning a VLSI circuit |
| US7643874B2 (en) * | 2001-10-24 | 2010-01-05 | Power Paper Ltd. | Dermal patch |
| KR101028788B1 (en) | 2001-10-24 | 2011-04-14 | 파워 페이퍼 리미티드 | Controlled Delivery Device and Method of Active Material into Skin |
| US6823202B2 (en) * | 2002-04-01 | 2004-11-23 | Iomed, Inc. | Iontophoretic power supply |
| US6866856B2 (en) | 2002-12-31 | 2005-03-15 | Avon Products, Inc. | Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis |
| KR200327534Y1 (en) | 2003-05-30 | 2003-09-22 | 홍명학 | Apparatus for caring skin |
| US7479133B2 (en) | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
| US7477941B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of exfoliating the skin with electricity |
| JP2005245521A (en) | 2004-03-01 | 2005-09-15 | Japan Natural Laboratory Co Ltd | Beautiful skin or beauty system using iontophoresis device, ultrasonic facial device and cosmetic additives. |
| US20060100567A1 (en) * | 2004-07-30 | 2006-05-11 | Rocky Mountain Biosystems, Inc | Microsurgical tissue treatment system |
| EP1671670A1 (en) | 2004-12-14 | 2006-06-21 | STX Sprl | Apparatus for electrically inhibiting facial muscles |
| KR200403033Y1 (en) | 2005-09-16 | 2005-12-07 | 이상홍 | Portable skin care device for beauty pack |
| US20070092571A1 (en) * | 2005-10-25 | 2007-04-26 | Schur Henry B | Non-irritating formulation and method for the intradermal delivery of substances |
| US7945320B2 (en) | 2007-08-17 | 2011-05-17 | Isis Biopolymer, Inc. | Iontophoretic drug delivery system |
| EP2242537A1 (en) | 2007-12-10 | 2010-10-27 | Isis Biopolymer LLC | Iontophoretic drug delivery device and software application |
| US20090299267A1 (en) | 2008-05-28 | 2009-12-03 | Isis Biopolymer Llc | Iontophoretic drug delivery system with procedure window |
| US20100286590A1 (en) | 2009-05-08 | 2010-11-11 | Isis Biopolymer Llc | Iontophoretic device with improved counterelectrode |
| US8747383B2 (en) | 2009-12-18 | 2014-06-10 | University Medical Pharmaceuticals Corp. | Process and system for iontophoretic wrinkle reduction |
-
2010
- 2010-12-16 US US12/970,224 patent/US8747383B2/en active Active
- 2010-12-17 RU RU2012130389/12A patent/RU2012130389A/en not_active Application Discontinuation
- 2010-12-17 WO PCT/US2010/061029 patent/WO2011075646A2/en active Application Filing
- 2010-12-17 EP EP10838291.2A patent/EP2512283A4/en not_active Ceased
-
2014
- 2014-06-06 US US14/298,190 patent/US9913977B2/en active Active
-
2018
- 2018-03-12 US US15/918,441 patent/US20180193637A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050000455A1 (en) * | 2003-07-01 | 2005-01-06 | Havermans Cornelis Christianus Franciscus | Milking installation |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012130389A (en) | 2014-01-27 |
| US20110190724A1 (en) | 2011-08-04 |
| EP2512283A2 (en) | 2012-10-24 |
| EP2512283A4 (en) | 2013-07-31 |
| WO2011075646A3 (en) | 2011-10-27 |
| US8747383B2 (en) | 2014-06-10 |
| US20140288527A1 (en) | 2014-09-25 |
| WO2011075646A2 (en) | 2011-06-23 |
| US9913977B2 (en) | 2018-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180193637A1 (en) | Process and system for iontophoretic wrinkle reduction | |
| US11896821B2 (en) | Systems and methods for tissue treatment | |
| US7979117B2 (en) | Device and method for controlled delivery of active substance into the skin | |
| US7643874B2 (en) | Dermal patch | |
| CN1607970B (en) | Skin patch | |
| US20140378555A1 (en) | Facial treatment device | |
| AU2002363106A1 (en) | Device and method for controlled delivery of active substance into the skin | |
| US20100228180A1 (en) | Power Source Electrode Treatment Device | |
| AU2002347567A1 (en) | Dermal patch | |
| KR20110002210A (en) | Functional stagnation | |
| KR20140146914A (en) | Connector device being connected to earphone connecting port of mobile terminal for providing electrical stimulus through electrical pad attached to skin surface | |
| KR100899100B1 (en) | Skin treatment apparatus | |
| KR20100080647A (en) | Electric low frequency type roller niddle | |
| TWI274583B (en) | Device for stimulating muscle to contract and relax | |
| KR20230091270A (en) | A collagen-producing portable beauty device that maximizes the anti-aging effect that stimulates skin cells using microcurrents | |
| CN113797443A (en) | A remote intelligent health biological device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |